Alume Biosciences, Inc., has revealed the first patient has been dosed a in Phase 3 Pivotal Study of ALM-488 (NCT05377554) in patients undergoing head and neck surgery.
ALM-488 is a peptide-dye conjugate designed to highlight nerves with fluorescence in real time during surgery.
Nullam et interdum sapien, eu facilisis erat. Etiam eget quam nisi. Integer imperdiet eros vel lorem pellentesque, non ornare libero aliquam. Phasellus nec urna molestie, pellentesque nisi at, volutpat odio. Mauris pulvinar efficitur neque at pretium. Nunc euismod turpis ante, et porttitor diam auctor sed. Ut erat metus, tincidunt a malesuada nec, blandit ut felis. Nullam pulvinar ac dolor at euismod. Curabitur scelerisque ac urna in cursus. Nulla nisi elit, consectetur a sem ac, laoreet condimentum massa
